Meeting
2020 ASCO Virtual Scientific Program
Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations.
Authors
Paul K. Paik
Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY
Paul K. Paik , Linda Su Hyun Ahn , Andrew J. Plodkowski , Pang-Dian Fan , Charles M. Rudin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02417701
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9607)
DOI
10.1200/JCO.2020.38.15_suppl.9607
Abstract #
9607
Poster Bd #
373
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228.
First Author: Paul K. Paik
Poster
2018 ASCO Annual Meeting
Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.
First Author: Paul K. Paik
Poster
2023 ASCO Annual Meeting
ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).
First Author: Sukhmani Kaur Padda
Poster
2023 ASCO Annual Meeting
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).
First Author: Joshua E. Reuss